Citius Oncology, Inc. CTOR
0.51 USD +0.01 (+2.10%)
At closeNov 9, 2026, 4:30 AM EST
0.47 -0.04 -7.36%
Pre-market · Nov 9, 4:30 AM ET
0.5023 Day range 0.541
0.491 52-week range 1.83
- YTD
- -49.05%
- 1 year
- -64.62%
News
prnewswire.com Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
benzinga.com Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment itius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius